Table 1.
Demographic and clinical characteristics in Primary.
| Sjögren’s Syndrome Patients (pSS) | |
|---|---|
| Features | pSS (n = 134) |
| Demographics | |
| Age, years (range) | 55 (29–83) |
| Sex (F/M) | 133/1 |
| Disease duration (years) | 5.62 ± 4.51 |
| Inflammation markers | |
| CRP (mg/L) | 3.73 ± 3.02 (0.20–24.40) |
| ESR (mm/h) | 26.89 ± 15.10 (0–76) |
| Clinical parameters | |
| Schirmer ≤ 5 mm/5 min | 3.14 ± 2.12 (0–17) |
| Foci number ≥ 1 focus/4 mm2 | 2.42 ± 1.28 (0.5–8.0) |
| SSDAI score (Min–Max) | 2.12 ± 1.63 (0–6) |
| SSDDI score (Min–Max) | 1.35 ± 1.05 (0–5) |
| ESSDAI score (Min–Max) | 3.15 ± 3.89 (0–19) |
| Anti-Ro UI/mL (%) | 32.24 ± 58.96 (31.34) |
| Anti-La UI/mL (%) | 12.42 ± 25.09 (12.68) |
| ANA, n (%) | 64 (47.76) |
| FR positive UI/mL (%) | 32.06 ± 34.55 (53.73) |
| Treatment * | |
| Prednisone, n (%) | 15 (11.19) |
| Hydroxychloroquine, n (%) | 75 (55.97) |
| Azathioprine, n (%) | 26 (19.40) |
| Methotrexate, n (%) | 29 (21.64) |
Data provided on average (minimum and maximum). Accounts; ESR; erythrocyte sedimentation rate, FR; rheumatoid factor, SSDAI; Sjogren’s Disease Activity Rate, SSDDI; Sjogren’s Disease Damage Index, ESSDAI; the activity rate of EULAR Sjogren’s syndrome disease. * Treatment include monotherapy and polytherapy with immunosuppressors/immunomodulators drugs.